Using injected LY2 cells [96], cells derived from 4NQO treatment [97], or cells with a SMAD-4 mutation to overexpress TGF-β, this study found a durable reduction in mouse tumor size and identified immune permissive tumor niches that promoted therapy response [95]. Here, TGFB1 is linked to neoplasm.